, Volume 12, Issue 2, pp 119-123
Date: 25 May 2013

Current Management of HBV Pre and Post Liver Transplant

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The introduction of the new DAAs Entecavir and Tenofovir have had a major impact on liver transplant for hepatitis B virus (HBV) infection. These agents have been shown to rescue patients with decompensated HBV in a manner similar to Lamivudine but without the same concern about resistance. The use of these agents post liver transplant with HBIG reduce HBV recurrence to <1 %. Increasingly they are being used to reduce long term use of HBIG although the timing of HBIG withdrawal and whether it should be applied to all HBV infected recipients requires further study.